SEC Form 4 · accession 0001209191-15-041137
TG THERAPEUTICS, INC. · TGTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Biotechnologies S.A.S.U. LFB
10% Owner
Period of report
Feb 17, 2015
Accepted (ET)
May 11, 2015 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001001316
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 17, 2015 | P | 114,855 | $6.53 | A | 5,114,855 | D | |
| Common Stock | May 7, 2015 | X | 2,500,000 | $0.001 | A | 7,614,855 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrants to Purchase Common StockF1 | $0.001 | May 7, 2015 | X | 2,500,000 | D | — | Nov 9, 2022 | Common Stock | 2,500,000 | 0 | D |
Explanation of responses
- F1The warrant became exercisable following equity financings in which TG Therapeutics, Inc. received gross proceeds of at least $7,500,000.
Remarks
Exhibit List Exhibit 24 - Power of Attorney